Boston Scientific (NYSE:BSX) Receives "Buy" Rating from Needham & Company LLC

Key Points

• Boston Scientific's stock has received a “Buy” rating from Needham & Company LLC, with a price target of $121.00, indicating a potential upside of 24.04%.
• The company reported $0.75 earnings per share (EPS) for the last quarter, surpassing analyst estimates and demonstrating a 22.8% increase in year-over-year revenue.
• Institutional investors hold 89.07% of Boston Scientific's stock, showing strong support from hedge funds and other large investors.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $121.00 price target on the medical equipment provider's stock. Needham & Company LLC's target price would suggest a potential upside of 24.04% from the company's current price.

BSX has been the subject of a number of other reports. Canaccord Genuity Group set a $132.00 price objective on shares of Boston Scientific in a report on Wednesday. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Robert W. Baird boosted their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, Truist Financial boosted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $119.88.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $97.55 on Wednesday. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50. The firm has a market capitalization of $144.54 billion, a P/E ratio of 58.07, a P/E/G ratio of 2.34 and a beta of 0.65. The business has a fifty day simple moving average of $103.53 and a two-hundred day simple moving average of $102.13. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business earned $0.62 earnings per share. The business's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,214 shares of company stock worth $13,048,957. Company insiders own 0.50% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently added to or reduced their stakes in BSX. 1248 Management LLC purchased a new position in shares of Boston Scientific in the 1st quarter worth $26,000. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC purchased a new position in shares of Boston Scientific during the second quarter worth approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.